drugset
drugset / Trial / NCT03942653

Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma

NCT03942653 ↗

Phase 2 Active not recruiting 20 enrolled Manish Patel Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

A Phase II, multi-center, single-arm, non-blinded study combining androgen deprivation therapy (ADT) and pembrolizumab for patients with metastatic or locally recurrent androgen receptor-positive salivary gland carcinoma, not amenable to surgery or radiation.

Timeline

Start
2019-05-30
Primary completion
2026-07
Completion
2026-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Goserelin Other / unclassified 3.6 mg Subcutaneous
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

salivary gland carcinoma